1K. Tobinai,Y. Kobayashi,M. Narabayashi,M. Ogura,Y. Kagami,Y. Morishima,T. Ohtsu,T. Igarashi,Y. Sasaki,T. Kinoshita,T. Murate. Feasibility and pharmacokinetic study of a chimeric anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) in relapsed B-cell lymphoma[J] 1998,Annals of Oncology(5):527～534
同被引文献20
1Edited by Mason D, Andre P, Bensussan A, et al. Leucocyte Typing Ⅶ, New York: Oxford University Press, 2002, P747 ～931.
2Mulford DA, Jurcic JG. Antibody-based treatment of acute myeloid leukaemia. Expert Opin Biol Ther, 2004, 4(1): 95-105.
3Cascavilla N, Melillo L, D'Arena G, et al. Minimally differentiated acute myeloid leukemia (AML M0 ): clinicobiological findings of 29 cases. Leuk Lymphoma, 2000,37: 105-113.
4Tallman MS. Relevance of pathologic classifications and diagnosis of acute myeloid leukemia to clinical trials and clinical practice.Cancer Treat Res, 2004, 121:45-67.
5Colita A, Belhabri A, Chelghoum Y, et al. Prognostic factors and treatment effects on survival in acute myeloid leukemia of M6 subtype: a retrospective study of 54 cases. Ann Oncol, 2001,12(4): 451-455.
6Athale UH, Razzouk BI, Raimondi SC, et al. Biology and outcome of childhood acute megakaryoblastic leukemia: a single institution's experience. Blood, 2001, 97(12): 3727-3732.
7Delaunay J, Vey N, Leblanc T, et al. Acute Leukemia French Association; Bordeaux-Grenoble Marseille-Toulouse cooperative groups. Prognosis of inv (16)/t (16 ; 16) acute myeloid leukemia (AML): a survey of 110 cases from the French AML Intergroup.Blood, 2003, 102(2): 462-469.
8Cho EK, Bang SM, Ahn JY, et al. Prognostic value of AML 1/ETO fusion transcripts in patients with acute myelogenous leukemia. Korean J InternMed, 2003, 18(1): 13-20.
9Schwartz S, Heinecke A, Zimmermann M, et al. Expression of the C-kit receptor (CD117) is a feature of almost all subtypes of de novo acute myeloblastic leukemia ( AML ), including cytogenetically good-risk AML, and lacks prognostic significance.Leuk Lymphoma, 1999, 34: 85-94.
10Kanda Y, Hamaki T, Yamamoto R, et al. The clinical significance of CD34 expression in response to therapy of patients with acute myeloid leukemia: an overview of 2483 patients from 22 studies. Cancer, 2000, 88(11): 2529-2533.
